XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating activities    
Net loss $ (277,813) $ (64,676)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,067 2,245
Amortization of investment discount (premiums) (3) (104)
In-process research and development charge 154,953  
Stock-based compensation expense 15,100 5,561
Change in operating lease right-of-use assets 4,634 1,985
Non-cash research and development license expense, net 0 264
Change in fair value of derivative liabilities 44,200 11,400
Change in fair value of contingent consideration liabilities 1,046  
Change in fair value of non-controlling equity investments (26,852) (517)
Other 63  
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (3,106) (4,215)
Collaboration receivable (50,000)  
Other long-term assets (197) (68)
Accounts payable 382 (53)
Accrued expenses and other liabilities 1,647 (239)
Operating lease liabilities 11,888 (1,801)
Deferred revenue 49,988 (12)
Other long-term liabilities (102)  
Net cash used in operating activities (71,105) (50,230)
Investing activities    
Purchases of property and equipment (27,662) (5,413)
Purchases of marketable securities (428,246) (135,959)
Maturities of marketable securities 162,525 88,198
Net cash acquired from Guide 620  
Purchase of long-term investment 0 (750)
Net cash used in investing activities (292,763) (53,924)
Financing activities    
Proceeds from initial public offering, net of underwriting discount 0 192,510
Proceeds from issuance of common shares, net of commissions 418,282  
Payment of equity offering costs (8,479) (1,665)
Proceeds from equipment financings   1,625
Repayment of equipment financings (1,046) (747)
Proceeds from exercise of stock options 4,955 512
Net cash provided by financing activities 413,712 192,235
Net change in cash, cash equivalents and restricted cash 49,844 88,081
Cash, cash equivalents and restricted cash—beginning of period 177,011 50,553
Cash, cash equivalents and restricted cash—end of period 226,855 138,634
Supplemental disclosure of cash flow information:    
Cash paid for interest 307 282
Supplemental disclosure of noncash investing and financing activities:    
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering   303,326
Property and equipment additions in accounts payable and accrued expenses 4,430 747
Operating lease liabilities arising from obtaining right-of-use assets 24,164 5,795
Fair value of common shares issued to settle success payment liability 30,000  
Contingent consideration liabilities assumed in asset acquisition 36,513  
Fair value of equity instruments issued in connection with asset acquisition $ 120,032  
Accretion of redeemable convertible preferred stock to redemption value, including dividends on preferred stock   $ 1,277